135 related articles for article (PubMed ID: 36305488)
1. Investing in Community Care Is an Important Goal and Need for Eliminating Hepatitis C in the United States: An Abolitionist Perspective.
Bhatnagar P; Canzater SL
Health Promot Pract; 2023 May; 24(3):411-414. PubMed ID: 36305488
[TBL] [Abstract][Full Text] [Related]
2. Advancing Hepatitis C Elimination through Opt-Out Universal Screening and Treatment in Carceral Settings, United States.
McNamara M; Furukawa N; Cartwright EJ
Emerg Infect Dis; 2024 Apr; 30(13):S80-S87. PubMed ID: 38561831
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C elimination among people who inject drugs in Mexico during the COVID-19 pandemic.
Márquez LK; Borquez A; Fleiz C; Magis-Rodríguez C; Rangel G; Strathdee SA; Martin NK
Gac Med Mex; 2022; 158(2):110-113. PubMed ID: 35763823
[TBL] [Abstract][Full Text] [Related]
4. Viral hepatitis C pandemic: Challenges and threats to its elimination.
Krekulova L; Honzák R; Riley LW
J Viral Hepat; 2021 May; 28(5):694-698. PubMed ID: 33550694
[TBL] [Abstract][Full Text] [Related]
5. Modeling HCV elimination recovery following the COVID-19 pandemic in the United States: Pathways to regain progress.
Blach S; Brown KA; Brown RS; Gholam PM; Terrault NA; Estes C; Razavi HA
J Infect Public Health; 2023 Jan; 16(1):64-70. PubMed ID: 36473359
[TBL] [Abstract][Full Text] [Related]
6. Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky.
Stone J; Fraser H; Young AM; Havens JR; Vickerman P
Int J Drug Policy; 2021 Feb; 88():102707. PubMed ID: 32151496
[TBL] [Abstract][Full Text] [Related]
7. A systematic review and meta-analysis of racial and ethnic disparities in hepatitis C antibody prevalence in United States correctional populations.
Larney S; Zaller ND; Dumont DM; Willcock A; Degenhardt L
Ann Epidemiol; 2016 Aug; 26(8):570-578.e2. PubMed ID: 27480479
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C Elimination During a Global Pandemic: A Case Study of Resilience in Action.
Facente SN; Grinstein R; Broussard J; Shost J; Azari S; Siruno J; Jimenez JA; Luetkemeyer AF; Burk K
Public Health Rep; 2022; 137(4):649-654. PubMed ID: 35403488
[TBL] [Abstract][Full Text] [Related]
9. Can hepatitis C be eradicated in the United States?
Edlin BR; Winkelstein ER
Antiviral Res; 2014 Oct; 110():79-93. PubMed ID: 25110202
[TBL] [Abstract][Full Text] [Related]
10. Universal opt-out screening for hepatitis C virus (HCV) within correctional facilities is an effective intervention to improve public health.
Morris MD; Brown B; Allen SA
Int J Prison Health; 2017 Sep; 13(3-4):192-199. PubMed ID: 28914118
[TBL] [Abstract][Full Text] [Related]
11. Incarceration, Inequality, and Hepatitis C Treatment: The Story of Two Southern States.
Wennerstrom A; Manogue S; Hardeo H; Robinson WT; Thomas DL; Irvin R
J Health Care Poor Underserved; 2023; 34(3):1129-1135. PubMed ID: 38015141
[TBL] [Abstract][Full Text] [Related]
12. A simple strategy to identify acute hepatitis C virus infection among newly incarcerated injection drug users.
Kim AY; Nagami EH; Birch CE; Bowen MJ; Lauer GM; McGovern BH
Hepatology; 2013 Mar; 57(3):944-52. PubMed ID: 23111904
[TBL] [Abstract][Full Text] [Related]
13. Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all.
Grebely J; Hajarizadeh B; Lazarus JV; Bruneau J; Treloar C;
Int J Drug Policy; 2019 Oct; 72():1-10. PubMed ID: 31345644
[TBL] [Abstract][Full Text] [Related]
14. Associations of criminal justice and substance use treatment involvement with HIV/HCV testing and the HIV treatment cascade among people who use drugs in Oakland, California.
Lambdin BH; Kral AH; Comfort M; Lopez AM; Lorvick J
Addict Sci Clin Pract; 2017 Jun; 12(1):13. PubMed ID: 28610602
[TBL] [Abstract][Full Text] [Related]
15. Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis.
Cunningham EB; Wheeler A; Hajarizadeh B; French CE; Roche R; Marshall AD; Fontaine G; Conway A; Bajis S; Valencia BM; Presseau J; Ward JW; Degenhardt L; Dore GJ; Hickman M; Vickerman P; Grebely J
Int J Drug Policy; 2023 Jan; 111():103917. PubMed ID: 36542883
[TBL] [Abstract][Full Text] [Related]
16. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
[TBL] [Abstract][Full Text] [Related]
17. Abolitionist Reimaginings of Health.
Khan ZH; Iwai Y; DasGupta S
AMA J Ethics; 2022 Mar; 24(3):E239-246. PubMed ID: 35325526
[TBL] [Abstract][Full Text] [Related]
18. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries.
Maticic M; Pirnat Z; Leicht A; Zimmermann R; Windelinck T; Jauffret-Roustide M; Duffell E; Tammi T; Schatz E
Harm Reduct J; 2020 Nov; 17(1):89. PubMed ID: 33213481
[TBL] [Abstract][Full Text] [Related]
19. Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness-implementation trial evaluating an integrated model of HCV care (DRIVE-C: DRug use & Infections in ViEtnam-hepatitis C).
Rapoud D; Quillet C; Pham Minh K; Vu Hai V; Nguyen Thanh B; Nham Thi Tuyet T; Tran Thi H; Molès JP; Vallo R; Michel L; Feelemyer J; Weiss L; Lemoine M; Vickerman P; Fraser H; Duong Thi H; Khuat Thi Hai O; Des Jarlais D; Nagot N; Laureillard D;
BMJ Open; 2020 Nov; 10(11):e039234. PubMed ID: 33208326
[TBL] [Abstract][Full Text] [Related]
20. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
